Enhabit, Inc. (NYSE:EHAB – Get Free Report) CAO Collin Mcquiddy sold 1,403 shares of Enhabit stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $13.61, for a total value of $19,094.83. Following the sale, the chief accounting officer directly owned 3,991 shares of the company’s stock, valued at approximately $54,317.51. The trade was a 26.01% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Enhabit Stock Up 0.1%
Shares of EHAB traded up $0.02 during midday trading on Wednesday, reaching $13.62. 2,806,514 shares of the stock were exchanged, compared to its average volume of 2,568,830. The company has a market cap of $690.55 million, a price-to-earnings ratio of -151.28 and a beta of 1.56. The company has a quick ratio of 1.63, a current ratio of 1.63 and a debt-to-equity ratio of 0.76. Enhabit, Inc. has a 12-month low of $6.47 and a 12-month high of $13.68. The firm has a 50 day simple moving average of $11.39 and a 200-day simple moving average of $9.49.
Enhabit (NYSE:EHAB – Get Free Report) last announced its quarterly earnings results on Wednesday, March 4th. The company reported $0.14 EPS for the quarter, meeting the consensus estimate of $0.14. Enhabit had a positive return on equity of 4.71% and a negative net margin of 0.43%.The business had revenue of $270.40 million during the quarter, compared to analysts’ expectations of $270.56 million. Research analysts forecast that Enhabit, Inc. will post 0.22 EPS for the current year.
Hedge Funds Weigh In On Enhabit
Analysts Set New Price Targets
Several research analysts have recently commented on EHAB shares. Oppenheimer downgraded shares of Enhabit from an “outperform” rating to a “market perform” rating in a report on Monday, February 23rd. Leerink Partners boosted their price target on Enhabit from $9.50 to $13.80 and gave the stock a “market perform” rating in a research report on Monday, February 23rd. TD Cowen reiterated a “hold” rating and set a $13.80 price target (up from $12.00) on shares of Enhabit in a research note on Friday, March 6th. Citigroup reissued a “buy” rating on shares of Enhabit in a report on Tuesday, December 16th. Finally, Wolfe Research set a $12.00 price objective on Enhabit in a research note on Thursday, January 8th. Two research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $13.57.
Check Out Our Latest Report on Enhabit
Enhabit Company Profile
Enhabit, Inc (NYSE: EHAB) is a national provider of home-based healthcare services, offering a continuum of care designed to support patients in the comfort of their own homes. The company’s core mission is to deliver personalized clinical and non-clinical services that help individuals recover from illness or injury, manage chronic conditions, and, when necessary, receive compassionate end-of-life care. Enhabit’s business model centers on combining skilled clinical care with patient-centric service coordination to optimize outcomes and enhance the overall care experience.
The company’s service portfolio includes skilled nursing, physical, occupational and speech therapies, personal care assistance, palliative care and hospice services.
Read More
- Five stocks we like better than Enhabit
- The gold chart Wall Street is terrified of…
- What a Former CIA Agent Knows About the Coming Collapse
- Elon Musk already made me a “wealthy man”
- Unlocked: Elon Musk’s Next Big IPO
- 1,500 Banks Just Handed the Fed Your Bank Account
Receive News & Ratings for Enhabit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enhabit and related companies with MarketBeat.com's FREE daily email newsletter.
